Celericon Therapeutics G.m.b.H. was founded on 1st March 2018 and is registered in Salzburg/Austria as a 100% subsidiary of the Paracelsus Medical University (PMU) in Salzburg, Austria, prepared to work with scientific and commercial partners.

PMU engages actively in Exosome-directed research and development since 2011.

The PMU GMP laboratory is one of a few academic institutions in Europe holding an unrestricted license for the manufacturing of MSCs and MSC-derived vesicular secretome fractions (VSF).